You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product menu

Power Reimagined

Indication
Vocabria injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.1

Introducing: Every 2-Month VOCABRIA (cabotegravir) + REKAMBYS (rilpivirine)

Calendar icon

Every-2-month VOCABRIA + REKAMBYS is generally well-tolerated with data out to 3 years1-3

Safety and Tolerability
Shield icon

Phase 3 trials established non-inferior efficacy to daily HIV therapy1-5

Learn More about Efficacy
Tick boxes icon

Every-2-month VOCABRIA + REKAMBYS was preferred by 9 out of 10 trial patients vs daily oral therapy with BIC/FTC/TAF6

Patient Preferences

SOLAR: First head-to-head data comparing Q2M dosing for HIV-1 vs daily oral therapy

Discover key findings from the SOLAR study

Discover SOLAR

*Two months between doses is on the continuation phase of treatment.

References
  1. VOCABRIA Suspension for Injection Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/vocabria-600-mg-prolonged-release-suspension-for-injection-35220/spc#tabs Last accessed: March 2024.
  2. REKAMBYS Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/rekambys-35258/spc Last accessed: March 2024.
  3. Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112-1123.
  4. Orkin C, Arasteh K, Hernández-Mora MG, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. Published online ahead of print: March 4, 2020. doi:10.1056/NEJMoa1909512.
  5. Overton ET, Richmond G, Rizzardini G, et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly dosing: Week 48 results from the ATLAS-2M Study. Presented at Conference on Retroviruses and Opportunistic Infections (CROI): March 8-11, 2020; Boston, MA.
  6. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety and tolerability of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV, 12 month results (SOLAR): A randomised open-label, phase 3b non-inferiority trial. The Lancet HIV. 2023. Published Online 8th August 2023. https://doi.org/10.1016/S2352-3018(23)00136-4

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

HIV-1=human immunodeficiency virus type 1.

REKAMBYS (rilpivirine long acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies.

All other trademarks are owned by the ViiV Healthcare group, or its licensor. 
©2022 GSK group of companies. All rights reserved.

Date of Preparation: March 2024 PM-IE-CBR-WCNT-230001